Bird Flu (H5N1 Avian Influenza) Vaccine News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

U.S. To Test Vaccines in Poultry as Way to Curb Bird Flu Outbreak
FRIDAY, Feb. 10, 2023 – U.S. health officials are considering using vaccines in poultry to stem an ongoing outbreak of bird flu. Scientists will begin testing the first vaccines for birds in years as the spread of avian influenza has killed about... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 10, 2023 Category: General Medicine Source Type: news

Avian H5N1 (Bird) Flu: Why Experts Are Worried —And What You Should Know
The U.S. government has a stash of bird flu vaccines, but if a pandemic is announced, it could take more than six months for enough vaccines to be made for the entire population. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 8, 2023 Category: Pharmaceuticals Authors: Arianna Johnson, Forbes Staff Tags: Innovation /innovation Healthcare /healthcare Breaking breaking-news Trending Explainer Trending-Explainer Source Type: news

Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adultsXofluza is the first influenza antiviral with a new mechanism of action in almost 20 years, stopping viral replication faster thanoseltamivirSingle-doseXofluza helps reduce the societal burden of influenza by helping patients recover quickly and by preventing infection in individuals following contact with someone with the virusBasel, 12 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC...
Source: Roche Investor Update - January 12, 2023 Category: Pharmaceuticals Source Type: news

Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adultsXofluza is the first influenza antiviral with a new mechanism of action in almost 20 years, stopping viral replication faster thanoseltamivirSingle-doseXofluza helps reduce the societal burden of influenza by helping patients recover quickly and by preventing infection in individuals following contact with someone with the virusBasel, 12 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC...
Source: Roche Media News - January 12, 2023 Category: Pharmaceuticals Source Type: news

News at a glance: Snags in emissions monitoring, negotiations on biodiversity, and a drug for sleeping sickness
CLIMATE SCIENCE Volcano and NASA deliver blows to climate monitoring Efforts to monitor global greenhouse gas emissions suffered two setbacks last week—one by chance, one by choice. In Hawaii, the first eruption of the Mauna Loa volcano since 1984 has cut off road access and power to a famed summit lab that has monitored atmospheric carbon dioxide (CO 2 ) levels since 1958. Although lava flows have so far spared the lab, which is run by the National Oceanic and Atmospheric Administration (NOAA), measurements are unlikely to resume for several months. That means tracking data will have to...
Source: ScienceNOW - December 8, 2022 Category: Science Source Type: news

A New Lab-Made COVID-19 Virus Puts Gain-of-Function Research Under the Microscope
On October 14, a team of scientists at Boston University released a pre-print study reporting that they had created a version of SARS-CoV-2 combining two features of different, existing strains that boosted its virulence and transmissibility. Scientists and the public raised questions about the work, which refocused attention on such experiments, and prompted the U.S. government to investigate whether the research followed protocols for these kinds of studies. The concerns surround what is known as gain-of-function studies, in which viruses, bacteria, or other pathogens are created in the lab—either intentionally or ...
Source: TIME: Science - October 27, 2022 Category: Science Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

U.S. weighs crackdown on experiments that could make viruses more dangerous
.news-article__hero--featured .parallax__element{ object-position: 50% 40%; -o-object-position: 50% 40%; } .scroll-wrapper { overflow-x: auto; } .scroll-wrapper .news-article__figure__image{ width: 2680px; max-width: none; padding-bottom: .75rem; } .scroll-fade-before, .scroll-fade-after { position: absolute; width: 1.5rem; transition-duration: .1s; opacity: 1; } .scroll-fade-before { left: 1rem; /*margin-left: -1px;*/ background: linear-gradient(90deg, #fff, #fff 35%, hsla(0, 0%, 100%, 0)); } .scroll-fade-after { right: 1rem; /*margin-right: -1px;*/ background: linear-gradient(270deg, #fff, #fff 3...
Source: ScienceNOW - October 19, 2022 Category: Science Source Type: news

Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of ageThe FDA also approved Xofluza to prevent influenza in children aged five years and older following contact with an infected personBasel, 12 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years o...
Source: Roche Investor Update - August 12, 2022 Category: Pharmaceuticals Source Type: news

Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of ageThe FDA also approved Xofluza to prevent influenza in children aged five years and older following contact with an infected personBasel, 12 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years o...
Source: Roche Media News - August 12, 2022 Category: Pharmaceuticals Source Type: news

GSK signs agreement to support pandemic preparedness in Europe
GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for the reservation of future production and supply of 85 million doses of its pandemic influenza vaccine Adjupanrix [pandemic influenza vaccine (split virion, inactivated, adjuvanted)]. (Source: World Pharma News)
Source: World Pharma News - August 1, 2022 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Wrestling with bird flu, Europe considers once-taboo vaccines
Science,<a href="https://www.science.org/toc/science/376/6594">Volume 376, Issue 6594</a>, Page 682-683, May 2022. (Source: ScienceNOW)
Source: ScienceNOW - May 12, 2022 Category: Science Authors: Erik Stokstad Source Type: news

H5N1 Vaccine Readied for a Possible Influenza Pandemic H5N1 Vaccine Readied for a Possible Influenza Pandemic
Adjuvanted H5N1 influenza vaccine has been shown to be highly immunogenic in younger and older adults. It is being developed in light of a possible H5N1 influenza pandemic that could cause global harm.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 8, 2022 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news

Bless you! Meet the flu hunters trying to stop the next pandemic in its tracks
Remember flu? Despite lockdowns holding it at bay, a small group of scientists is searching the globe for deadly new strains – and to work out what to put in next winter’s vaccinesLast month, a small group of international scientists met to decide an issue critical to the health of millions of people all over the planet. For once, it wasn ’t about coronavirus, although these experts know a lot about that, too. The task in hand was to save us from a bug we’ve been fighting since before the days of Hippocrates, the first doctor to describe it in 400BC. It’s an adversary potentially as much of a threat as Covid. The...
Source: Guardian Unlimited Science - March 19, 2022 Category: Science Authors: Sarah Boseley. Portraits: David Levene Tags: Flu Vaccines and immunisation Bird flu Health Society Flu pandemic & wellbeing World Health Organization Coronavirus Infectious diseases Life and style Medical research Science World news Microbiology Source Type: news

Influenza Vaccinations During the COVID-19 Pandemic Influenza Vaccinations During the COVID-19 Pandemic
This report assessed the potential impact of the COVID-19 pandemic on influenza vaccination coverage. How did vaccination during Sept-Dec 2020 compare with the corresponding period in prior years?Morbidity & Mortality Weekly Report (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 31, 2022 Category: Consumer Health News Tags: Public Health & Prevention Journal Article Source Type: news

Fully Ready to Kill, Shockingly Unprepared to Save Lives
Credit: Albert Gonzalez Farran / UNAMIDBy Baher KamalMADRID, Jan 14 2022 (IPS) While absolutely ready to kill, with the biggest military powers spending in 2020 nearly two trillion US dollars on weapons, the world is shockingly unprepared to save the lives of millions of unarmed, innocent civilian victims of wars… and other man-made catastrophes. The military spending data come from the Stockholm International Peace Research Institute (SIPRI), which also reports that global nuclear arsenals grow as states continue to modernise, thus sharply increasing the dangers of an unimaginable number of victims of the most devastati...
Source: IPS Inter Press Service - Health - January 14, 2022 Category: International Medicine & Public Health Authors: Baher Kamal Tags: Development & Aid Economy & Trade Global Global Governance Headlines Health Peace Poverty & SDGs TerraViva United Nations Source Type: news